| Literature DB >> 33430189 |
Susanne Röhr1,2, Andrea Zülke1, Melanie Luppa1, Christian Brettschneider3, Marina Weißenborn4, Flora Kühne5, Isabel Zöllinger5, Franziska-Antonia Zora Samos6, Alexander Bauer6, Juliane Döhring7, Kerstin Krebs-Hein7, Anke Oey8, David Czock4, Thomas Frese6, Jochen Gensichen5, Walter E Haefeli4, Wolfgang Hoffmann9,10, Hanna Kaduszkiewicz7, Hans-Helmut König3, Jochen René Thyrian9,10, Birgitt Wiese8, Steffi G Riedel-Heller1.
Abstract
Targeting dementia prevention, first trials addressing multiple modifiable risk factors showed promising results in at-risk populations. In Germany, AgeWell.de is the first large-scale initiative investigating the effectiveness of a multi-component lifestyle intervention against cognitive decline. We aimed to investigate the recruitment process and baseline characteristics of the AgeWell.de participants to gain an understanding of the at-risk population and who engages in the intervention. General practitioners across five study sites recruited participants (aged 60-77 years, Cardiovascular Risk Factors, Aging, and Incidence of Dementia/CAIDE dementia risk score ≥ 9). Structured face-to-face interviews were conducted with eligible participants, including neuropsychological assessments. We analyzed group differences between (1) eligible vs. non-eligible participants, (2) participants vs. non-participants, and (3) between intervention groups. Of 1176 eligible participants, 146 (12.5%) dropped out before baseline; the study population was thus 1030 individuals. Non-participants did not differ from participants in key sociodemographic factors and dementia risk. Study participants were M = 69.0 (SD = 4.9) years old, and 52.1% were women. The average Montreal Cognitive Assessment/MoCA score was 24.5 (SD = 3.1), indicating a rather mildly cognitively impaired study population; however, 39.4% scored ≥ 26, thus being cognitively unimpaired. The bandwidth of cognitive states bears the interesting potential for differential trial outcome analyses. However, trial conduction is impacted by the COVID-19 pandemic, requiring adjustments to the study protocol with yet unclear methodological consequences.Entities:
Keywords: AgeWell.de; RCT; cluster-randomized controlled trial; cognitive function; dementia; general practitioner; intervention; lifestyle; prevention; primary care; trial
Mesh:
Year: 2021 PMID: 33430189 DOI: 10.3390/ijerph18020408
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390